Choosing the optimal therapy for metastatic renal cell carcinoma: Insights from a real‐world comparative study
Both IOIO and IOTKI therapies were effective. Therapy selection could be better tailored to patient characteristics by including factors such as the presence of bone metastases and BMI. This study enhances understanding of how patient-specific factors interact with different treatment modalities, potentially guiding more personalized treatment decisions in clinical practice for mRCC.
Authors
- Yukari Bando (ORCID: https://orcid.org/0000-0001-7736-1216)
- Takuto Hara (ORCID: https://orcid.org/0000-0003-4524-2815)
- Tomoaki Terakawa (ORCID: https://orcid.org/0000-0002-4447-6516)
- Yasuyoshi Okamura (ORCID: https://orcid.org/0000-0002-8466-3949)
- Yoji Hyodo (ORCID: https://orcid.org/0000-0002-9553-0981)
- Koji Chiba (ORCID: https://orcid.org/0000-0001-5575-0667)
- Kotaro Suzuki (ORCID: https://orcid.org/0000-0003-4589-9251)
- Hideaki Miyake (ORCID: https://orcid.org/0000-0003-0563-4160)
- Jun Teishima (ORCID: https://orcid.org/0009-0004-7018-5095)
Institutions
- Kobe University (JP)
Publication Details
- Journal
- International Journal of Urology
- Published
- 2024-10-13
- DOI
- https://doi.org/10.1111/iju.15590
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42